Address
1 Evertrust Plaza
Jersey City, NJ 07302-6548
United States of America (the)
Phone
201 884 5485
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
18
First IPO Date
May 02, 2014
| Name | Title | Pay | Year Born |
| David Gonzalez Angulo | Chief Executive Officer, President & Director | 948,911 | 1965 |
| Scott Sukenick | Chief Legal Officer & Corporate Secretary | 642,667 | 1978 |
| Ivor Macleod | Chief Financial Officer | 651,123 | 1961 |
| Daniella Gigante | Vice President of Human Resources & Information Technology | 0 | N/A |
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.